AstraZeneca PLC (AZN) is a publicly traded Healthcare sector company. As of May 20, 2026, AZN trades at $187.48 with a market cap of $285.23B and a P/E ratio of 0.00. AZN moved +1.54% today. Year to date, AZN is +101.64%; over the trailing twelve months it is +164.94%. Its 52-week range spans $61.24 to $212.71. Analyst consensus is strong buy with an average price target of $214.28. Rallies surfaces AZN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
AstraZeneca Gains FDA Approval for Baxfendy, Targets $5 Billion Hypertension Market: AstraZeneca won FDA approval for Baxfendy, an aldosterone synthase inhibitor poised to address 23 million US patients uncontrolled on two or more blood pressure treatments. Baxfendy, from the $1.8B CinCor acquisition, aims for over $5 billion in annual sales and is undergoing heart failure trials.
| Metric | Value |
|---|---|
| Price | $187.48 |
| Market Cap | $285.23B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 1.59% |
| 52-Week High | $212.71 |
| 52-Week Low | $61.24 |
| Volume | 1.42M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
15 analysts cover AZN: 0 strong buy, 13 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $214.28.